Drug Type Small molecule drug |
Synonyms Emraclidine |
Target |
Mechanism M4 receptor modulators(Muscarinic acetylcholine receptor M4 modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC20H21F3N4O |
InChIKeyDTCZNKWBDTXEBS-UHFFFAOYSA-N |
CAS Registry2170722-84-4 |
Start Date10 May 2024 |
Sponsor / Collaborator |
Start Date04 Mar 2024 |
Sponsor / Collaborator |
Start Date15 Aug 2023 |
Sponsor / Collaborator |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Psychotic Disorders | Phase 2 | BG | 30 Jun 2022 | |
Psychotic Disorders | Phase 2 | US | 30 Jun 2022 | |
Psychotic Disorders | Phase 2 | HU | 30 Jun 2022 | |
Schizophrenia | Phase 2 | HU | 30 Jun 2022 | |
Schizophrenia | Phase 2 | BG | 30 Jun 2022 | |
Schizophrenia | Phase 2 | US | 30 Jun 2022 | |
Alzheimer Disease | Phase 2 | US | 30 Jan 2022 |
Study | Phase | Population | Analyzed Enrollment | Group | Results | Evaluation | Publication Date |
---|
No Data |